Targeting stanniocalcin-1-expressing tumor cells elicits efficient antitumor effects in a mouse model of human lung
Kotaro Abe1, Masahiko Kanehira1,2, Shinya Ohkouchi3
1Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
Abstract:
Lung cancer is the most common cause of cancer-related death in developed countries; therefore, the generation of effective targeted therapeutic regimens is essential. Recently, gene therapy approaches toward malignant cells have emerged as attractive molecular therapeutics. Previous studies have indicated that stanniocalcin-1 (STC-1), a hormone involved in calcium and phosphate homeostasis, positively regulates proliferation, apoptosis resistance, and glucose metabolism in lung cancer cell lines. In this study, we investigated if targeting STC-1 in tumor cells could be a promising strategy for lung cancer gene therapy. We confirmed that STC-1 levels in peripheral blood were higher in lung cancer patients than in healthy donors and that STC-1 expression was observed in five out of eight lung cancer cell lines. A vector expressing a suicide gene, uracil phosphoribosyltransferase (UPRT), under the control of the STC-1 promoter, was constructed (pPSTC-1 -UPRT) and transfected into three STC-1-positive cell lines, PC-9, A549, and H1299. When stably transfected, we observed significant cell growth inhibition using 5-fluorouracil (5-FU) treatment. Furthermore, growth of the STC-1-negative lung cancer cell line, LK-2 was significantly arrested when combined with STC-1-positive cells transfected with pPSTC-1 -UPRT. We believe that conferring cytotoxicity in STC-1-positive lung cancer cells using a suicide gene may be a useful therapeutic strategy for lung cancer.
Insights
Targeting stanniocalcin-1 (STC-1) in lung cancer cells via gene therapy shows promise. A suicide gene delivered using the STC-1 promoter effectively inhibited tumor growth in preclinical models.
Area of Science:
- Molecular Biology
- Oncology
- Gene Therapy
Background:
- Lung cancer is a leading cause of cancer mortality, necessitating novel therapeutic strategies.
- Stanniocalcin-1 (STC-1) is implicated in regulating proliferation and apoptosis resistance in lung cancer cells.
Purpose of the Study:
- To investigate the potential of targeting STC-1 for lung cancer gene therapy.
- To develop and evaluate a suicide gene therapy approach utilizing the STC-1 promoter.
Main Methods:
- Measured STC-1 levels in lung cancer patients and cell lines.
- Constructed a suicide gene vector (pPSTC-1 -UPRT) driven by the STC-1 promoter.
- Transfected STC-1-positive lung cancer cell lines (PC-9, A549, H1299) and evaluated efficacy with 5-fluorouracil (5-FU) and co-culture assays.
Main Results:
- Elevated STC-1 levels were observed in lung cancer patients and positive cell lines.
- Transfected cells exhibited significant growth inhibition upon 5-FU treatment.
- Co-culture of STC-1-positive transfected cells with STC-1-negative cells led to significant growth arrest of the latter.
Conclusions:
- Targeting STC-1 with a suicide gene represents a viable strategy for lung cancer gene therapy.
- This approach demonstrates potential for selective tumor cell killing and bystander effects.
